- Published on
Emergency and Acute Medicine: Warfarin Complications
Warfarin is a widely used oral anticoagulant that works by inhibiting vitamin K–dependent clotting factors (II, VII, IX, and X), thereby affecting both the extrinsic and common coagulation pathways. It is commonly prescribed for conditions such as venous thromboembolism, atrial fibrillation, and prosthetic heart valves. Its therapeutic effect is monitored using the International Normalized Ratio, with typical target ranges of 2–3 or 2.5–3.5 depending on indication. However, due to its narrow therapeutic window and numerous interactions, warfarin is associated with significant complications, most notably bleeding.
Bleeding is the most common complication, occurring in up to 15% of patients annually, with major bleeding events in about 5% and fatal bleeding (most often Intracranial hemorrhage) in less than 1%. The risk of bleeding increases significantly when the INR exceeds 4. Patients may present with a wide spectrum of symptoms, ranging from occult bleeding to life-threatening hemorrhage involving the gastrointestinal tract, central nervous system, or retroperitoneum. Conversely, subtherapeutic INR levels may result in breakthrough thrombosis, particularly in high-risk patients.
Several factors predispose patients to unstable INR levels and complications, including advanced age (>75 years), comorbidities such as hypertension, diabetes, renal or liver disease, malignancy, and hyperthyroidism. Drug and dietary interactions are especially important: antibiotics, Amiodarone, NSAIDs, and certain herbal supplements (e.g., ginkgo, garlic) can increase INR, while drugs like Rifampin, carbamazepine, and high vitamin K intake can decrease it. Warfarin is contraindicated in pregnancy due to its teratogenic effects.
A unique complication is warfarin-induced skin necrosis, which typically occurs within the first week of therapy and is associated with protein C deficiency. It presents as painful skin lesions that progress to necrosis with central eschar formation. Limb gangrene may also occur due to venous thrombosis. In cases of overdose or ingestion of long-acting anticoagulants (e.g., “superwarfarins” found in rodenticides), patients may initially be asymptomatic but develop prolonged coagulopathy requiring extended monitoring.
Evaluation requires a thorough history, including indication for anticoagulation, recent dose changes, medication interactions, and prior INR values. Physical examination should focus on signs of bleeding (e.g., ecchymosis, pallor, hypotension) and subtle neurologic changes suggestive of intracranial bleeding. Laboratory testing includes PT/INR, CBC, renal and liver function tests, and type and crossmatch if bleeding is suspected. Imaging, particularly CT scans, should be obtained liberally to detect occult bleeding, especially in trauma patients or those with neurologic symptoms.
Management depends on the INR level and presence of bleeding. For patients with INR <5 and no bleeding, the next dose may be held or reduced with close monitoring. For INR 5–9 without bleeding, holding warfarin and administering Vitamin K1 at 1–5 mg PO may be appropriate, especially in high-risk patients. For INR ≥9 without bleeding, vitamin K 2.5–5 mg PO is recommended. In cases of serious or life-threatening bleeding (any INR), immediate reversal is required with vitamin K 10 mg IV (slow infusion over 10–30 minutes) along with clotting factor replacement.
Rapid reversal is best achieved using Prothrombin complex concentrate, which contains clotting factors II, VII, IX, and X. Dosing is weight- and INR-dependent: 25 U/kg for INR 2–3.9, 35 U/kg for INR 4–5.9, and 50 U/kg for INR ≥6. PCC is preferred in cases of intracranial hemorrhage, massive bleeding, or when volume overload is a concern. Alternatively, Fresh frozen plasma may be used, typically 3–4 units (≈1 L), though it carries risks such as fluid overload and slower INR correction. In refractory or complex cases, adjuncts such as factor VIIa may be considered.
Disposition depends on severity. Patients with active bleeding, especially involving the CNS, GI tract, or retroperitoneum, require admission and often ICU-level care. Stable patients with asymptomatic supratherapeutic INR and reliable follow-up may be discharged with close monitoring. Follow-up within 24–48 hours for repeat INR testing is essential.
A key clinical pearl is to maintain a low threshold for imaging in anticoagulated patients, even after minor trauma, as serious bleeding may occur without obvious symptoms. Additionally, vitamin K should generally not be given for INR <5 without bleeding, and IV vitamin K should be reserved for severe cases due to the rare but serious risk of anaphylaxis.
0 Comments
